Overview
Broken String Biosciences is a forefront genomics company that develops advanced cell and gene therapies through cutting-edge genome editing tools such as CRISPR-Cas9. Positioned at the nexus of biotechnology innovation, the company is committed to enhancing the safety and efficacy of gene editing by mitigating off-target edits, which pose potential adverse effects. Their proprietary INDUCE-seq® technology is pioneering in precisely mapping DNA breaks, ultimately refining the specificity of genome-editing capabilities.
- Website: [brokenstringbio.com](https://www.brokenstringbio.com/)
- Headquarters: Biodata Innovation Centre, Wellcome Genome Campus, Hinxton, Cambridge, England, CB10 1DR
- VAT Number: GB 372 333 704
- Contact: info@brokenstringbio.com | +44(0)1223 786 071
Key Technologies
INDUCE-seq®
The INDUCE-seq® platform is instrumental in identifying and characterizing genomic breaks, ensuring enhanced safety and efficacy in gene and cell therapy protocols through its high-resolution structural DNA analysis.
Catalyst Program
This initiative accelerates the development of gene-editing therapies by providing early access to developers, enabling rapid detection of both on- and off-target edits. It is a strategic asset for advancing therapies swiftly and accurately.
Significant Achievements and Developments
- Series A Funding: In September 2023, Broken String Biosciences raised $15 million to further its growth initiatives.
- Leadership Appointments:
- In 2024, Laurence Reid and Brad Crutchfield joined the Board of Directors.
- Steve Becker became Chief Commercial Officer in July 2024, focusing on commercial operations expansion and market launches.
- Gavin Burns, appointed as VP of Quality and Operations in November 2023, brings extensive experience in quality assurance from the genomics sector.
Strategic Partnerships and Collaborations
- Francis Crick Institute Collaboration: Formed to advance research on Amyotrophic Lateral Sclerosis (ALS) announced in May 2024.
- Industry Conferences: CEO Felix Dobbs and CCO Steve Becker are prominent figures at key industry events like #AGBT2025, showcasing technological advancements and engaging with potential partners.
Company Leadership
- Felix Dobbs, PhD - Co-founder & CEO, guiding the company's strategic direction. [LinkedIn](https://uk.linkedin.com/in/felixdobbs)
- Simon Reed, PhD - Co-founder & CSO, leading scientific innovation and cancer studies. [LinkedIn](https://uk.linkedin.com/in/simon-reed-1063842b)
- Vincent Smith, PhD - CTO, responsible for advancing technological development.
- Steve Becker - Chief Commercial Officer, driving market entry for new technologies. [LinkedIn](https://www.linkedin.com/in/stevebecker)
- Patrick van Eijk, PhD - Co-founder & Staff Scientist, essential in R&D specializing in functional genomics.
- Gavin Burns, PhD - VP of Quality and Operations, managing quality to ensure gene-editing product efficacy. [LinkedIn](https://uk.linkedin.com/in/gb1977)
Future Vision
Broken String Biosciences envisions revolutionizing healthcare through its genomic editing innovations, emphasizing the highest precision and safety standards aimed at transforming the treatment of genetic disorders. The company's dedication establishes it as a leader in biotechnological and genomic sectors.
Competitor Profiling
1. Clock.bio
- Industry Focus: Biotechnology Research, Regenerative Medicine
- Technology: Develops regenerative medicines using human pluripotent stem cells to counteract cellular aging.
- Headquarters: Cambridge, UK
- Company Size: 2-10 employees
- Financials: Recently raised $5.3M in seed funding.
- Developments: Recognized in the #21toWatch 2025 shortlist for longevity science advancements.
2. Dunad Therapeutics
- Industry Focus: CNS Disease, Oncology, Drug Development
- Technology: Utilizes tunable covalent chemistry for targeted disease treatments.
- Headquarters: Cambridge, UK
- Company Size: 11-50 employees
- Financials: Raised $24 million in Series A.
- Activities: Developing targeted protein degradation therapies.
3. CardiaTec Biosciences
- Industry Focus: Cardiovascular Biotechnology
- Technology: Employs AI and human omics for novel cardiovascular drugs.
- Headquarters: Cambridge, UK
- Company Size: 2-10 employees
- Financials: $6.5M in seed funding.
- Developments: Progress in computational drug discovery platform.
4. Eigen Therapeutics
- Industry Focus: Oncology, Combination Therapies
- Technology: Designs therapies considering tumor heterogeneity to enhance cancer treatment.
- Headquarters: Redwood City, CA, US
- Developments: Enhancing targeted cancer therapies through co-therapy focus.
5. EpiBiologics
- Industry Focus: Targeted Protein Degradation
- Technology: Develops antibody therapies targeting extracellular or transmembrane proteins.
- Headquarters: San Mateo, CA, US
- Company Size: Not specified
- Financials: Raised $73 million from funding rounds.
- Trends: Enhancing pipeline with focus on immunotherapy and protein sciences.
Strategic Insights
The competitive landscape for Broken String Biosciences includes firms advancing in regenerative medicine, targeted therapeutics, computational drug discovery, and protein degradation technologies. Maintaining a competitive edge with its sophisticated DNA break mapping technology, Broken String Biosciences can further enhance its market stance through strategic collaborations in gene therapy and computational biology.
